Amphastar Pharmaceuticals (NASDAQ:AMPH) Reaches New 1-Year Low - What's Next?

Key Points

• Amphastar Pharmaceuticals shares have hit a new 52-week low, trading down to $20.40, with a last trading price of $21.02.
• Analysts predominantly maintain a "hold" rating on the stock, with the consensus price target set at $32.33 after several revisions from major firms.
• Recent activity from institutional investors shows significant inflows, with some firms increasing their stakes by over 192% in recent quarters.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) reached a new 52-week low on Friday . The company traded as low as $20.40 and last traded at $21.02, with a volume of 2232 shares trading hands. The stock had previously closed at $20.95.

Analyst Upgrades and Downgrades

AMPH has been the subject of a number of research reports. Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th. Wells Fargo & Company reduced their price objective on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. Finally, JPMorgan Chase & Co. restated a "neutral" rating and set a $30.00 target price (down from $45.00) on shares of Amphastar Pharmaceuticals in a report on Monday, May 12th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $32.33.

Amphastar Pharmaceuticals Trading Up 0.2%

The firm has a market cap of $1.01 billion, a PE ratio of 7.77 and a beta of 0.76. The firm has a fifty day simple moving average of $23.65 and a two-hundred day simple moving average of $26.53. The company has a current ratio of 2.95, a quick ratio of 2.02 and a debt-to-equity ratio of 0.80.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

A number of large investors have recently modified their holdings of the stock. TD Asset Management Inc grew its holdings in shares of Amphastar Pharmaceuticals by 20.2% during the 1st quarter. TD Asset Management Inc now owns 2,212,142 shares of the company's stock worth $64,130,000 after acquiring an additional 371,856 shares during the period. Fuller & Thaler Asset Management Inc. grew its stake in Amphastar Pharmaceuticals by 11.5% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,263,598 shares of the company's stock worth $36,632,000 after purchasing an additional 130,672 shares during the period. Epoch Investment Partners Inc. raised its holdings in Amphastar Pharmaceuticals by 14.5% in the first quarter. Epoch Investment Partners Inc. now owns 1,261,307 shares of the company's stock worth $36,565,000 after purchasing an additional 160,034 shares in the last quarter. Boston Trust Walden Corp lifted its position in Amphastar Pharmaceuticals by 24.2% during the first quarter. Boston Trust Walden Corp now owns 1,215,624 shares of the company's stock valued at $35,241,000 after buying an additional 236,704 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Amphastar Pharmaceuticals by 9.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,198,590 shares of the company's stock valued at $44,503,000 after buying an additional 105,288 shares in the last quarter. Institutional investors own 65.09% of the company's stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.